Binding Services Agreement (the “Agreement”) between Wilson Wolf Manufacturing Corporation (“Wilson Wolf”) and Marker Therapeutics, Inc. (“Marker”) Dated April 21, 2022Binding Services Agreement • April 26th, 2022 • Marker Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Overview Gas permeable rapid expansion technology, commonly called G-Rex®, is a technology created by Wilson Wolf and routinely used throughout the field of cell therapy and gene-modified cell therapy for activation, transduction, expansion, and/or concentration of various cells, including T cells and natural killer cells (the “G-Rex”). Marker is developing clinical stage antigen specific cell therapies capable of recognizing tumor associated antigens in the absence of genetic engineering (collectively, the “Marker Therapies”). Marker has created Quality Management System in compliance with Title 21 Parts 211, 600, and 1271 (the “Quality Management System”). Marker utilizes a FDA registered manufacturing facility that manufactures Marker Therapies using a GMP-compliant, linearly scalable, G-Rex based T-cell manufacturing process including manufacturing pods within a warehouse type facility (collectively, the “GMP Manufacturing Process”) and use of a cell culture non-proprietary media f
BINDING SERVICES AGREEMENTBinding Services Agreement • April 13th, 2021 • California
